68Ga-Pentixafor PET/CT offers high contrast image for the detection of CXCR4 expression in recurrent glioma.

Conclusions: It has been proven in few recent preclinical and clinical studies (mainly multiple myeloma, isolated solid tumors including lung cancer) that 68Ga-Pentixafor uptake is tied up specifically to CXCR 4 expression. The results of this preliminary study demonstrate that 68Ga-Pentixafor PET imaging in GBM (know to have high CXCR4 expression) is viewed to open-up new theranostics applications (with beta and alpha radionuclides) for long term survival benefits. However, the diagnostic utility of this tracer needs to be validated in a large cohort of patients through multi-centric trials.

Source: Journal of Nuclear Medicine - May 20, 2019 Category: Nuclear Medicine Authors: Watts, A., Arora, D., Kumar, N., Thakur, S., Basher, R., Radotra, B., Singh, B. Tags: Brain Imaging Reloaded II Source Type: research